注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Deciphera Pharmaceuticals Inc是一家专注于发现、开发和提供药物治疗癌症患者的生物制药公司。该公司开发了激酶生物学的开关控制激酶抑制剂平台,以执行其战略,开发广泛的药物组合。该公司已经批准了一种药物,QINLOCK,这是一种开关控制激酶抑制剂,用于治疗第四线胃肠道间质瘤(GIST)。此外,该公司正在开发三种临床阶段候选药物,其中包括Vimseltinib(DCC-3014)-集落刺激因子1受体(CSF1R)激酶抑制腱鞘巨细胞瘤(TGCT),Rebastinib-TEK酪氨酸激酶(TIE2)激酶抑制晚期或转移性实体瘤,和DCC-3116-ULK激酶抑制突变RAS/RAF癌。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Steven L. Hoerter | 50 | 2018 | President, CEO & Director |
James A. Bristol | 76 | 2007 | Independent Director |
John S. Condeelis | - | - | Member of Scientific Advisory Board |
Dennis Leo Walsh | 55 | 2015 | Independent Director |
Jean-Yves Blay | 61 | 2015 | Member of Scientific Advisory Board |
Ron Squarer | 56 | 2019 | Independent Chairman |
Filip Janku | 48 | 2015 | Member of Scientific Advisory Board |
Michele De Palma | - | - | Member of Scientific Advisory Board |
John de Groot | - | - | Member of Scientific Advisory Board |
Patricia L. Allen | 61 | 2016 | Independent Director |
Frank S. Friedman | 65 | 2019 | Independent Director |
F. Stephen Hodi | - | 2015 | Member of Scientific Advisory Board |
John R. Martin | 62 | 2015 | Independent Director |
Edward J. Benz | 77 | 2016 | Independent Director |
Susan L. Kelley | 68 | 2019 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核